In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal AdenocarcinomaDecember 22, 2017
[Journal of Gastrointestinal Oncology] This research evaluates the use of capecitabine and oxaliplatin (CAPOX) for first or second-line treatment of locally advanced or metastatic PDAC.
In a retrospective study of SEER-Medicare data, researchers determined the survival outcomes of women with breast cancer and comorbid mental illness vs those without mental illness.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.
A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.
Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.
Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
In a prospective study, researchers assessed survival and quality of life measures for patients with advanced cancer in relation to where they are discharged from hospital: postacute care (PAC), hospice, or home without hospice.
Comparison study via questionnaires assessed patients' and oncologists' views on likelihood of dying as a result of treatment shortly after beginning intensive or nonintensive chemotherapy for AML, and their views on prognosis 1 month later.
Researchers randomly assigned 478 patients with R/R MM to receive carfilzomib 70 mg/m2 once weekly plus dexamethasone or carfilzomib 27 mg/m2 twice weekly plus dexamethasone.
Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.
A retrospective analysis of 28 studies determined that overall response rates for patients with ITP were similar treated with hydroxychloroquine, danazol, or dapsone in the second-line setting were similar.
Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.
Retrospective analysis of data from more than 19,000 women revealed that all-cause mortality rates are higher in women with breast cancer who have a prior diagnosis of a mental illness.
Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.
Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.
Reducing the initial dose of sorafenib was shown to have some benefits — such as reduced pill burden, lower costs, and decreased AE-related discontinuation rates — and OS was noninferior compared with the standard dose in patients with hepatocellular carcinoma.
The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.
Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.
Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.
The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.
Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for CliniciansJuly 24, 2017
A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.
Two recent studies examined the benefits of using a 3D bioabsorbable marker to indicate the tumor bed in women with breast cancer who underwent breast conserving surgery (BCS).
An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.
Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older PatientsJune 27, 2017
Results from a sub-analysis of the impact of age on the safety and efficacy of lenvatinib in patients with RR-DTC in the SELECT trial showed that lenvatinib significantly increased PFS.
Regular use of NSAIDs after diagnosis of colorectal cancer correlated with improved survival in survivors with KRAS wild-type tumors.
Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|